uniQure N.V. 10-Q

Item 5. Other Information ​ During the three months ended March 31, 2026, the following adopted a “ Rule 10b5-1 trading arrangement ” (as defined in Item 408(a) of Regulation S-K) that is intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act and our policies on insider trading: ​ ​ ​ ​ ​ Name & Title Date Adopted (1) Aggregate Number of Ordinary Shares to be Purchased or Sold Pursuant to Trading Arrangement Expiration Date (2) Madhavan Balachandran , Non-executive Director March 10, 2026 21,685 December 31, 2026 ​ (1) Date of adoption of this Rule 10b5-1 trading arrangement is in accordance with applicable SEC rules and regulations. The first trade pursuant to this Rule 10b5-1 trading arrangement will be, in accordance with applicable SEC rules and regulations, on a date after the date of adoption of the Rule 10b5-1 trading arrangement, to the extent triggered under its terms. ​ (2) The Rule 10b5-1 trading arrangement is scheduled to expire on the date listed in the table, subject to earlier termination upon the sale of all shares subject to the Rule 10b5-1 trading arrangement, or as otherwise provided in the Rule 10b5-1 trading arrangement. ​ Other than those disclosed above, none of our directors or officers adopted, modified, or terminated a “Rule 10b5-1 trading arrangement” or “ non-Rule 10b5-1 trading arrangement ,” in each case as defined in Item 408 of Regulation S-K, during the three months ended March 31, 2026. ​ Item 6. Exhibits ​ See the Exhibit Index immediately preceding the signature page to this Quarterly Report on Form 10-Q for a list of exhibits filed or furnished with this report, which Exhibit Index is incorporated herein by reference. ​ ​ 33 Table of Contents EXHIBIT INDEX ​ ​ ​ ​ ​ 10.1*+ Termination and Amendment Agreement, dated April 15, 2026, by and between uniQure biopharma B.V. and CSL Behring LLC. ​ ​ 31.1* Certification of Chief Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities and Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. ​ ​ 31.2* Certification of Chief Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities and Exchange Act of 1934, as amended, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 . ​ ​ 32.1± Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 . ​ ​ 101* The following financial information from our Quarterly Report on Form 10-Q for the period ended March 31, 2026, filed with the Securities and Exchange Commission on May 5, 2026, is formatted in Inline Extensible Business Reporting Language (“iXBRL”): (i) Consolidated Balance Sheets; (ii) Consolidated Statements of Operations and Comprehensive Loss; (iii) Consolidated Statements of Shareholders’ Equity; (iv) Consolidated Statements of Cash Flows; and (v) Notes to Consolidated Financial Statements (tagged as blocks of text). ​ ​ 104* The cover page from our Quarterly Report on Form 10-Q for the period ended March 31, 2026, filed with the Securities and Exchange Commission on May 5, 2026, is formatted in Inline Extensible Business Reporting Language (“iXBRL”). ​ * Filed herewith. ± Furnished herewith. ​ + Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K. ​ ​ ​ ​ 34 Table of Contents SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ​ ​ UNIQURE N.V. ​ ​ ​ ​ ​ By: /s/ Matthew Kapusta Matthew Kapusta Chief Executive Officer (Principal Executive Officer) ​ ​ ​ ​ ​ By: /s/ Christian Klemt Christian Klemt Chief Financial Officer (Principal Financial and Accounting Officer) ​ Date: May 5, 2026 ​ ​ 35